Palisade Bio (FRA:7NS0) Short-Term Capital Lease Obligation : €0.12 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Palisade Bio Short-Term Capital Lease Obligation?

Palisade Bio's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.12 Mil.

Palisade Bio's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 (€0.11 Mil) to Dec. 2023 (€0.11 Mil) and increased from Dec. 2023 (€0.11 Mil) to Mar. 2024 (€0.12 Mil).

Palisade Bio's annual Short-Term Capital Lease Obligation stayed the same from Dec. 2021 (€0.10 Mil) to Dec. 2022 (€0.10 Mil) but then increased from Dec. 2022 (€0.10 Mil) to Dec. 2023 (€0.11 Mil).

Palisade Bio Short-Term Capital Lease Obligation Historical Data

The historical data trend for Palisade Bio's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palisade Bio Short-Term Capital Lease Obligation Chart

Palisade Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

0.14

0.10

0.11

Palisade Bio Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial											0.10	0.10	0.11	0.11	0.12

Palisade Bio Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Palisade Bio Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Palisade Bio's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Palisade Bio (FRA:7NS0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palisade Bio Inc (FRA:7NS0) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

PALI:USA

Address

5800 Armada Drive, Suite 2A, Carlsbad, CA, USA, 92008

Website

https://www.palisadebio.com

Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.

Palisade Bio (FRA:7NS0) Headlines

No Headlines